Is GANX or KTTA more profitable?

Pasithea Therapeutics' return on equity of -49.49% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Pasithea Therapeutics N/A -49.49% -46.81%

Does the media favor SERA or KTTA?

In the previous week, Sera Prognostics had 6 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 10 mentions for Sera Prognostics and 4 mentions for Pasithea Therapeutics. Sera Prognostics' average media sentiment score of 0.44 beat Pasithea Therapeutics' score of 0.37 indicating that Sera Prognostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KTTA or YARW?

In the previous week, Yarrow Bioscience had 11 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 15 mentions for Yarrow Bioscience and 4 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.37 beat Yarrow Bioscience's score of 0.35 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Yarrow Bioscience 3 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, KTTA or RNTX?

Rein Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$1.58 N/A Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A

Is KTTA or RNTX more profitable?

Rein Therapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -49.49% -46.81% Rein Therapeutics N/A N/A -63.69%

Does the media favor KTTA or RNTX?

In the previous week, Pasithea Therapeutics had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 4 mentions for Pasithea Therapeutics and 2 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.08 beat Pasithea Therapeutics' score of 0.37 indicating that Rein Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rein Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, PMVP or KTTA?

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A Pasithea Therapeutics N/A N/A -$20.43M -$1.58 N/A

Is PMVP or KTTA more profitable?

Pasithea Therapeutics' return on equity of -49.49% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PMV Pharmaceuticals N/A -78.11% -70.13% Pasithea Therapeutics N/A -49.49% -46.81%

Does the media prefer PMVP or KTTA?

In the previous week, PMV Pharmaceuticals and PMV Pharmaceuticals both had 4 articles in the media. PMV Pharmaceuticals' average media sentiment score of 0.90 beat Pasithea Therapeutics' score of 0.37 indicating that PMV Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PMV Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pasithea Therapeutics (KTTA) Competitors

$0.49 -0.01 (-2.00%)

As of 02:35 PM Eastern

Compare

KTTA vs. GANX, SERA, YARW, RNTX, and PMVP

Should you buy Pasithea Therapeutics stock or one of its competitors? Pasithea Therapeutics's main competitors and comparable companies include Gain Therapeutics (GANX), Sera Prognostics (SERA), Yarrow Bioscience (YARW), Rein Therapeutics (RNTX), and PMV Pharmaceuticals (PMVP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pasithea Therapeutics compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Gain Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

In the previous week, Pasithea Therapeutics had 3 more articles in the media than Gain Therapeutics. MarketBeat recorded 4 mentions for Pasithea Therapeutics and 1 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.15 beat Pasithea Therapeutics' score of 0.37 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gain Therapeutics	Positive
Pasithea Therapeutics	Neutral

Gain Therapeutics has higher revenue and earnings than Pasithea Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,505.58	-$20.16M	-$0.50	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A

Gain Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 334.78%. Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 500.00%. Given Pasithea Therapeutics' higher probable upside, analysts clearly believe Pasithea Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pasithea Therapeutics' return on equity of -49.49% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Pasithea Therapeutics	N/A	-49.49%	-46.81%

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Gain Therapeutics and Pasithea Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Sera Prognostics?

Sera Prognostics (NASDAQ:SERA) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Pasithea Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Pasithea Therapeutics	N/A	-49.49%	-46.81%

Sera Prognostics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

Sera Prognostics presently has a consensus target price of $5.50, indicating a potential upside of 170.14%. Pasithea Therapeutics has a consensus target price of $3.00, indicating a potential upside of 500.00%. Given Pasithea Therapeutics' higher probable upside, analysts clearly believe Pasithea Therapeutics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pasithea Therapeutics has lower revenue, but higher earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	1,004.00	-$31.93M	-$0.67	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A

In the previous week, Sera Prognostics had 6 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 10 mentions for Sera Prognostics and 4 mentions for Pasithea Therapeutics. Sera Prognostics' average media sentiment score of 0.44 beat Pasithea Therapeutics' score of 0.37 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Sera Prognostics beats Pasithea Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Yarrow Bioscience?

Pasithea Therapeutics (NASDAQ:KTTA) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, Yarrow Bioscience had 11 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 15 mentions for Yarrow Bioscience and 4 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.37 beat Yarrow Bioscience's score of 0.35 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Yarrow Bioscience	3 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 1.5% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pasithea Therapeutics has higher earnings, but lower revenue than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A
Yarrow Bioscience	$570K	124.88	-$26.48M	-$14.64	N/A

Pasithea Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market.

Pasithea Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 500.00%. Yarrow Bioscience has a consensus target price of $58.00, indicating a potential upside of 117.55%. Given Pasithea Therapeutics' higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pasithea Therapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Pasithea Therapeutics' return on equity of -49.49% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-49.49%	-46.81%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Summary

Pasithea Therapeutics beats Yarrow Bioscience on 8 of the 15 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Rein Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Rein Therapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-49.49%	-46.81%
Rein Therapeutics	N/A	N/A	-63.69%

Pasithea Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 500.00%. Rein Therapeutics has a consensus target price of $6.00, indicating a potential upside of 719.67%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rein Therapeutics is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Pasithea Therapeutics had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 4 mentions for Pasithea Therapeutics and 2 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.08 beat Pasithea Therapeutics' score of 0.37 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rein Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pasithea Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

Rein Therapeutics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 1.5% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Rein Therapeutics beats Pasithea Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Pasithea Therapeutics compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

PMV Pharmaceuticals has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 10.2% of PMV Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, PMV Pharmaceuticals and PMV Pharmaceuticals both had 4 articles in the media. PMV Pharmaceuticals' average media sentiment score of 0.90 beat Pasithea Therapeutics' score of 0.37 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PMV Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PMV Pharmaceuticals currently has a consensus price target of $4.33, indicating a potential upside of 193.79%. Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 500.00%. Given Pasithea Therapeutics' higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pasithea Therapeutics' return on equity of -49.49% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
Pasithea Therapeutics	N/A	-49.49%	-46.81%

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A

Summary

PMV Pharmaceuticals beats Pasithea Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KTTA vs. The Competition

Export

Metric	Pasithea Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.71M	$3.86B	$7.21B	$14.99B
Dividend Yield	N/A	3.65%	2.57%	11.71%
P/E Ratio	-0.32	14.53	273.61	25.47
Price / Sales	N/A	1,419.88	698.20	113.08
Price / Cash	N/A	108.94	77.71	51.48
Price / Book	0.21	15.22	10.40	6.34
Net Income	-$20.43M	-$22.78M	$3.49B	$358.32M
7 Day Performance	-12.23%	-0.50%	-0.12%	0.29%
1 Month Performance	4.06%	0.63%	-0.03%	-3.10%
1 Year Performance	-32.81%	39.38%	19.22%	6.52%

Pasithea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KTTA Pasithea Therapeutics	2.9698 of 5 stars	$0.49 -2.0%	$3.00 +512.2%	-35.0%	$16.37M	N/A	N/A	3
GANX Gain Therapeutics	2.6222 of 5 stars	$1.72 -6.0%	$7.50 +336.0%	+4.3%	$79.87M	$50K	N/A	20	Positive News
SERA Sera Prognostics	2.4632 of 5 stars	$2.00 -0.5%	$5.50 +175.0%	-35.8%	$79.29M	$80K	N/A	120
YARW Yarrow Bioscience	2.4974 of 5 stars	$29.11 -0.6%	$58.00 +99.2%	N/A	$78.22M	$570K	N/A	30	Short Interest Increase
RNTX Rein Therapeutics	3.1836 of 5 stars	$0.83 -4.1%	$6.00 +625.1%	-36.3%	$74.40M	N/A	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KTTA) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. GANX, SERA, YARW, RNTX, and PMVP

How does Pasithea Therapeutics compare to Gain Therapeutics?

Summary

How does Pasithea Therapeutics compare to Sera Prognostics?

Summary

How does Pasithea Therapeutics compare to Yarrow Bioscience?

Summary

How does Pasithea Therapeutics compare to Rein Therapeutics?

Summary

How does Pasithea Therapeutics compare to PMV Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. GANX, SERA, YARW, RNTX, and PMVP

How does Pasithea Therapeutics compare to Gain Therapeutics?

Which has more risk & volatility, GANX or KTTA?

Does the media refer more to GANX or KTTA?

Which has stronger valuation and earnings, GANX or KTTA?

Do analysts rate GANX or KTTA?

Is GANX or KTTA more profitable?

Do institutionals & insiders have more ownership in GANX or KTTA?

Summary

How does Pasithea Therapeutics compare to Sera Prognostics?

Is SERA or KTTA more profitable?

Which has more risk & volatility, SERA or KTTA?

Do analysts recommend SERA or KTTA?

Which has better valuation & earnings, SERA or KTTA?

Does the media favor SERA or KTTA?

Do insiders and institutionals believe in SERA or KTTA?

Summary

How does Pasithea Therapeutics compare to Yarrow Bioscience?

Does the media prefer KTTA or YARW?

Do insiders and institutionals hold more shares of KTTA or YARW?

Which has higher valuation and earnings, KTTA or YARW?

Which has more volatility and risk, KTTA or YARW?

Do analysts recommend KTTA or YARW?

Is KTTA or YARW more profitable?

Summary

How does Pasithea Therapeutics compare to Rein Therapeutics?

Is KTTA or RNTX more profitable?

Do analysts prefer KTTA or RNTX?

Does the media favor KTTA or RNTX?

Which has more risk & volatility, KTTA or RNTX?

Which has higher valuation and earnings, KTTA or RNTX?

Do institutionals and insiders believe in KTTA or RNTX?

Summary

How does Pasithea Therapeutics compare to PMV Pharmaceuticals?

Which has more volatility & risk, PMVP or KTTA?

Do institutionals and insiders believe in PMVP or KTTA?

Does the media prefer PMVP or KTTA?

Do analysts recommend PMVP or KTTA?

Is PMVP or KTTA more profitable?

Which has stronger valuation and earnings, PMVP or KTTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools